Berkeley Lights logo
Berkeley Lights BLI

Quarterly report 2023-Q2
added 08-14-2023

report update icon

Berkeley Lights Balance Sheet 2011-2026 | BLI

Annual Balance Sheet Berkeley Lights

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-60.5 M -151 M -223 M -61.2 M -79.9 M - - - - - - -

Long Term Debt

22.7 M 24.3 M 8.3 M 14.1 M 19.8 M - - - - - - -

Long Term Debt Current

3.29 M 2.94 M 1.91 M - - - - - - - - -

Total Non Current Liabilities

- - - 22.3 M 20.8 M - - - - - - -

Total Current Liabilities

45.5 M 32.8 M 29 M - - - - - - - - -

Total Liabilities

84 M 79 M 54.9 M 47.2 M 36.2 M - - - - - - -

Deferred Revenue

9.09 M 12.1 M 5.48 M 9.69 M 9.48 M - - - - - - -

Retained Earnings

-362 M -264 M -192 M -150 M -132 M - - - - - - -

Total Assets

226 M 287 M 300 M 131 M 134 M - - - - - - -

Cash and Cash Equivalents

86.5 M 178 M 234 M 81.3 M 99.9 M - - - - - - -

Book Value

142 M 208 M 245 M 83.8 M 97.6 M - - - - - - -

Total Shareholders Equity

142 M 208 M 245 M 83.8 M 97.6 M - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Berkeley Lights

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- 68.9 M 14.9 M 23.6 M 24.1 M 23.6 M 24.3 M 25.1 M 14.8 M 15.4 M 15.9 M 15.9 M 15.9 M 15.9 M 6.78 M 6.78 M 6.78 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

67.1 M 143 M 84 M 76.7 M 74.3 M 72.7 M 79 M 81 M 63.9 M 60.6 M 54.9 M 54.9 M 54.9 M 54.9 M 47.2 M 47.2 M 47.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

9.65 M 10.7 M 9.09 M 7.73 M 8.69 M 9.78 M 12.1 M 11.3 M 8.26 M 7.93 M 5.48 M 5.48 M 5.48 M 5.48 M 9.69 M 9.69 M 9.69 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-435 M -385 M -362 M -332 M -311 M -285 M -264 M -246 M -225 M -207 M -192 M -192 M -192 M -192 M -150 M -150 M -150 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

178 M 301 M 226 M 235 M 249 M 266 M 287 M 301 M 296 M 303 M 300 M 300 M 300 M 300 M 131 M 131 M 131 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

31 M 51.6 M 86.5 M 121 M 143 M 165 M 178 M 197 M 215 M 230 M 234 M 233 M 233 M 233 M 81 M 81 M 81 M - 99.9 M - - - 26.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

111 M 158 M 142 M 158 M 174 M 193 M 208 M 220 M 232 M 242 M 245 M 245 M 245 M 245 M 83.8 M 83.8 M 83.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

111 M 158 M 142 M 158 M 174 M 193 M 208 M 220 M 232 M 242 M 245 M 245 M 245 M 245 M 83.8 M 83.8 M 83.8 M 94.5 M 97.6 M - - - 23.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Berkeley Lights, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Adagene Adagene
ADAG
$ 2.91 5.05 % $ 164 M chinaChina
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 82.0 3.13 % $ 1.58 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.58 -1.53 % $ 16.2 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 29.29 0.93 % $ 2.41 B usaUSA
Biogen Biogen
BIIB
$ 176.18 0.77 % $ 25.7 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
BioNTech SE BioNTech SE
BNTX
$ 116.77 0.53 % $ 27.2 B germanyGermany
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.26 -3.55 % $ 7.84 B australiaAustralia
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.1 -1.2 % $ 8.92 B israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 10.15 -5.45 % $ 668 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.32 -1.69 % $ 428 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Coherus BioSciences Coherus BioSciences
CHRS
$ 2.33 5.19 % $ 219 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 223.95 0.67 % $ 5 B danmarkDanmark
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.99 -1.72 % $ 116 M franceFrance
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.66 1.9 % $ 1.52 B britainBritain
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 69.12 5.4 % $ 9.25 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.58 1.57 % $ 2.91 B usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.62 -0.31 % $ 77.2 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 22.96 -3.41 % $ 2.23 B franceFrance
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.11 1.15 % $ 4.36 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA